News
VTRS
15.04
+0.67%
0.10
Viatris presents positive Phase 3 data for investigational low-dose contraceptive patch at ACOG
PUBT · 14h ago
Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting
PR Newswire · 14h ago
Assessing Viatris (VTRS) Valuation After Xanax XR Recall And Quality Control Setback
Simply Wall St · 1d ago
24 Ideal 'Safer' April Buys Nabbed In 10 Years Of Dogcatcher Digging
Seeking Alpha · 1d ago
Weekly Report: what happened at VTRS last week (0420-0424)?
Weekly Report · 4d ago
Does Xanax XR Recall Over Dissolution Issues Change The Bull Case For Viatris (VTRS)?
Simply Wall St · 4d ago
Viatris' Q1 2026 Earnings: What to Expect
Barchart · 04/23 07:03
Weekly Report: what happened at VTRS last week (0413-0417)?
Weekly Report · 04/20 09:40
Notable healthcare headlines for the week: J&J, Abbott and Organon in focus
Seeking Alpha · 04/19 13:05
Viatris Inc. Stock Advances 4.8%, Outperforms Market
Dow Jones · 04/17 20:35
Viatris Inc. stock rises Friday, outperforms market
MarketWatch · 04/17 20:30
Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know
Barchart · 04/17 15:32
QSM Asset Management Loads Up 611,000 Mobileye Shares
The Motley Fool · 04/17 01:58
The 10 Healthcare stocks with the lowest forward P/E ratios
Seeking Alpha · 04/16 20:39
FDA Takes Step Forward on Testosterone Therapy for Men
Benzinga · 04/16 15:37
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Benzinga · 04/15 12:16
Viatris Ophthalmology Data At ASCRS Puts Valuation And Dividend In Focus
Simply Wall St · 04/14 21:07
Quant check on David Einhorn's Greenlight Capital holdings post Q1
Seeking Alpha · 04/14 09:50
Teva must face Mylan lawsuit over generic competition for Copaxone
Reuters · 04/13 19:18
Viatris to report first-quarter results, host webcast call
PUBT · 04/13 10:59
More
Webull provides a variety of real-time VTRS stock news. You can receive the latest news about Viatris Inc Ord Shs through multiple platforms. This information may help you make smarter investment decisions.
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.